Pattern of Antibiotic Use among Hospitalized Patients according to WHO Access, Watch, Reserve (AWaRe) Classification: Findings from a Point Prevalence Survey in Bangladesh

Md. Mahbubur Rashid 1,2,* (✉), Zubair Akhtar 1,3, Sukanta Chowdhury 1, Md. Ariful Islam 1, Shahana Parveen 1, Probir Kumar Ghosh 1, Aninda Rahman 4, Zobaidul Haque Khan 5, Khaleda Islam 5, Nitish Debnath 5, Mahmudur Rahman 6 and Fahmida Chowdhury 1

Abstract: For supporting antibiotic stewardship interventions, the World Health Organization (WHO) classified antibiotics through the AWaRe (Access, Watch, and Reserve) classification. Inappropriate use of antimicrobials among hospital-admitted patients exposes them to the vulnerability of developing resistant organisms which are difficult to treat. We aimed to describe the proportion of antibiotic use based on the WHO AWaRe classification in tertiary and secondary level hospitals in Bangladesh. A point prevalence survey (PPS) was conducted adapting the WHO PPS design in inpatients departments in 2021. Among the 1417 enrolled patients, 52% were female and 63% were from the 15–64 years age group. Nearly 78% of patients received at least one antibiotic during the survey period. Third-generation cephalosporins (44.6%), penicillins (12.3%), imidazoles (11.8%), aminoglycosides (7.2%), and macrolides (5.8%) were documented as highly used antibiotics. Overall, 64.0% of Watch, 35.6% of Access, and 0.1% of Reserve group antibiotics were used for treatment. The use of Watch group antibiotics was high in medicine wards (78.7%) and overall high use of Watch antibiotics was observed at secondary hospitals (71.5%) compared to tertiary hospitals (60.2%) (p-value of 0.000). Our PPS findings underscore the need for an urgent nationwide antibiotic stewardship program for physicians including the development and implementation of local guidelines and in-service training on antibiotic use.

Keywords: AWaRe; WHO; antibiotics; access; watch; Bangladesh; hospitals

1. Introduction

Irrational and inappropriate use of antimicrobials specifically antibiotics in humans, animals, and in the food chain leads to the acceleration of the emergence of antimicrobial resistance (AMR) or antibiotic resistance (ABR). A large proportion of the burden of infections occurs by resistant pathogens due to healthcare-associated infections (HAIs) [1]. The
increasing trend of resistant organisms subsequently leads to treatment failure, significant morbidity and mortality, and poses additional out-of-pocket expenditure and healthcare costs annually [2,3]. In 2019, about 4.95 million deaths were estimated to be associated with bacterial AMR and 1.27 million deaths were attributable to bacterial AMR [4]. Currently, the use of antibiotic consumption is escalating worldwide driven by rising purchasing capacity, health insurance, and the burden of various infectious diseases [5]. The overuse of antimicrobials in outpatients was also documented in Bangladesh due to both self-medication and physician’s prescriptions [6–8]. The problem necessitates two ways to draw attention: interrupting the transmission of resistant organisms and cautious use of antimicrobials in hospitals [9].

In the 68th World Health Assembly, the highest importance was given to AMR considering the health and economic consequences of adopting the global action plan for all member states [10]. The World Health Organization’s (WHO) expert committee developed the ‘AWaRe’ classification on using the Essential Medicine List (EML) in 2017 to support, strengthen, and monitor the antibiotic stewardship program and was further updated in 2021 [11]. The goal is to ensure the total consumption of Access group antibiotics at least 60% at the country level, and the index also helps to calculate the comparative use of narrow-spectrum and broad-spectrum antibiotics [12,13]. To understand the global prevalence of antimicrobial use and resistance with special emphasis on Low- and Middle-Income Countries (LMIC), the Global Point Prevalence Survey (GLOBAL-PPS) of antimicrobial use and resistance was developed after the 4th World Healthcare-Associated Infections and Antimicrobial Resistance Forum [14,15]. In accordance with the WHO, Bangladesh also adopted the Global Action Plan (GAP) and developed a National Action Plan (NAP) 2017–2022 for the containment of AMR. Although the country has started a surveillance system to generate reliable data on AMR, there remains a dearth of information on antimicrobial usage (AMU) or antibiotic usage (ABU). There is also a paucity of information regarding the antimicrobial prescription at inpatient departments which is a daunting barrier to the successful development and implementation of antimicrobial stewardship programs. Aligning with the Global-PPS and the WHO, a point prevalence survey was conducted at both government tertiary and secondary level acute care hospitals in Bangladesh. The objectives of the survey were to understand the prevalence of AMU, the distribution of antibiotic agents used, to improve AMU knowledge, and to identify the possible scope of intervention for promoting prudent use of antibiotics utilizing WHO’s ‘AWaRe’ classification.

2. Methods

2.1. Study Design and Study Population

The point prevalence survey on AMU among inpatients was the part of a larger project having the objective of understanding antimicrobial use in humans (at hospitals, communities, and pharmacies), commercial chicken, and aquaculture in Bangladesh through the ‘One Health’ approach. The survey was conducted in four acute care government hospitals (two tertiary and two secondary level hospitals) selected purposively in 2 administrative divisions of Bangladesh from 18 February to 6 April 2021. A structured survey questionnaire was adapted from WHO and Global-PPS design to assess the extent of antimicrobial prescribing patterns among the hospitalized patients at different wards of survey hospitals [16,17]. The survey was conducted among inpatients of medicine, surgery, gynae and obstetrics, and pediatric wards including intensive care units.

2.2. Inclusion Criteria

All patients admitted in the ward on the day of the survey from Saturday to Thursday in a week before 08:00 o’clock were included in the survey upon obtaining written informed consent from patients or caregivers [16,17].
2.3. Exclusion Criteria

Patients from outpatients or day-care patient facilities, nursing homes, psychiatric wards, long-term care wards, emergency departments, out-patient dialysis, discharged patients waiting for parents or relatives, and outpatient parenteral antimicrobial therapy were excluded from the survey [16,17]. Moreover, patients admitted in the selected wards after 8.00 o’clock or transferred from other wards to the selected wards after 8.00 o’clock, patients’ receiving topical and ophthalmologic antimicrobials, and treatment initiated after 08:00 o’clock on the day of survey were excluded.

2.4. Data Collection and Study Variables

Study physicians collected patient’s demographic and clinical information, indications for antimicrobial use, microbiological lab findings, and details of antimicrobial used. For secondary level hospitals (≤500 bedded), all eligible patients were enrolled, and for tertiary level hospitals (≥800 bedded), every 3rd patient of each ward was enrolled after securing a written informed consent. If a patient refused to join the survey, the next patient on the list was approached. A single hospital was completed within a maximum of three consecutive weeks from the onset of the first day of data collection with a special emphasis on one ward in one day to minimize the impact of patients moving between wards. For antimicrobial data, the study focused on antibacterials for systemic use, antiparasitics and antifungals for systemic use, antiprotozoals used as antibacterial agents, imidazoles derivatives, all antivirals, and antimalarials.

The indications for antimicrobial use were set in four categories such as Community Acquired Infection (CAI), Hospital Acquired Infection (HAI), Medical Prophylaxis (MP), and Surgical Prophylaxis (SP). CAI was considered if a patient was admitted in a hospital from home or their community with infection or symptoms of infection [5]. Moreover, if a patient developed an infection or symptoms of infection after >48 h of admission, they were registered as HAI [18]. Medical Prophylaxis (MP) was defined as antimicrobials which were used to prevent an infection in inpatients with medical conditions in absence of any diagnosis of communicable disease [5]. Similarly, SP was identified if antimicrobials were used to prevent infection at surgical sites [19]. The study physicians explored indications for antimicrobial use by interviewing patients or caregivers or treating doctors and by assessing the patients’ treatment sheets. Moreover, SP was classified in three categories depending on doses and duration on the day of survey; one dose of antimicrobial used for one day/multiple days (SP1), multiple doses used for one day (SP2), and multiple doses for more than one day (SP3). Patients’ age categories were adapted form Management Information System of the Directorate General of Health Services (DGHS) [20] where patients aged below 14 years are generally admitted in pediatric departments in government hospitals of Bangladesh.

2.5. Data Management and Statistical Analysis

The data were analyzed using the statistical software STATA 13.0 (Special edition). For descriptive analysis, hospital information, ward data, demographic and clinical information of patients, antimicrobial data were analyzed and illustrated in figures and tables. Continuous variables were reported by means (standard deviation) or medians (interquartile range). Bi-variate analysis was done using chi-square test to understand association among antibiotics use, sex, age-group, departments, history of surgery, use of devices, history of transfer from another hospital, and indications of antimicrobial use. Based on the findings of bivariate analysis and significance level \( p \leq 0.25 \), we performed multivariable logistic model to identify the independent associated variables. The results were reported as adjusted odds ratio (aOR) with a 95% confidence interval (CI). The distribution of antibiotics was analyzed using WHO AWaRe classification, 2021 [11].
2.6. Ethical Consideration

The Institutional Review Board (IRB) of International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), granted the approval to conduct the study after protocol review by the research review committee and ethical review committee. Permission and necessary support to implement this study at government hospitals were received from DGHS of Bangladesh Government. Informed written consents from patients or caregivers of pediatric and intensive care unit patients were obtained before commencing the data collection by explaining the purpose and scope of the study, assurance of the confidentiality of personal health information, and clarifying any questions.

3. Results

A total of 3140 eligible patients were admitted during the study period; among them, 892 patients (34.3%) were enrolled from 2599 eligible patients in two tertiary level hospitals and 525 patients (97.0%) were enrolled from 541 eligible patients in two secondary level hospitals. Thereby, the enrolment rate was 45.1% (1417/3140).

3.1. Demographic and Clinical Characteristics

Among the surveyed patients, female patients constituted 51.6%; 62.6% of patients were from the 15–64 years age group and 28.2% were from the 0–14 years age group which belong to the pediatric population (Table 1). Mean age of the enrolled patients was 31.1 years (SD: ±23.3). Overall, 49% of patients had primary to higher level of formal education. The majority of patients (36.1%) were involved in household work, 13.6% were farmers, and 28.4% were unemployed. Among the enrolled patients, 33.4% were from medicine wards, 28.2% from surgery wards, 22.4% from pediatric wards, and 15.9% from gynae and obstetric wards.

Table 1. Demographic and clinical characteristics of the patients enrolled in the point prevalence survey of antimicrobial usage at tertiary and secondary level hospitals in Bangladesh from February to April 2021.

| Characteristics                          | Tertiary Level Hospitals (N = 892) | Secondary Level Hospitals (N = 525) | Overall (N = 1417) |
|------------------------------------------|-----------------------------------|-----------------------------------|--------------------|
|                                          | n (%)                             | n (%)                             | n (%)              |
| **Sex**                                  |                                   |                                   |                    |
| Female                                   | 455 (51.0)                        | 276 (52.6)                        | 731 (51.6)         |
| Male                                     | 437 (48.9)                        | 249 (47.43)                       | 686 (48.4)         |
| **Age group**                            |                                   |                                   |                    |
| 0–14 years age group                     | 251 (28.1)                        | 148 (28.2)                        | 399 (28.2)         |
| 15–64 years age group                    | 561 (62.9)                        | 326 (62.1)                        | 887 (62.6)         |
| 65 years and above                       | 80 (9.0)                          | 51 (9.7)                          | 131 (9.2)          |
| **Mean age ± SD**                        | 31.2 (23.1)                       | 30.9 (23.5)                       | 31.1 (23.3)        |
| **Education level**                      |                                   |                                   |                    |
| No education                             | 453 (50.8)                        | 270 (51.4)                        | 723 (51.0)         |
| Primary                                  | 181 (20.3)                        | 80 (15.2)                         | 261 (18.4)         |
| Secondary                                | 176 (19.7)                        | 116 (22.1)                        | 292 (20.6)         |
| Higher                                   | 82 (9.2)                          | 59 (11.2)                         | 141 (10.0)         |
| Patient transfer from another hospital   | 218 (24.4)                        | 39 (7.4)                          | 257 (18.1)         |
| Patient hospitalized in last 3 months    | 138 (15.5)                        | 63 (12.0)                         | 201 (14.2)         |
| **Invasive device used**                 |                                   |                                   |                    |
| Central vascular catheter                | 11 (1.2)                          | 4 (1.0)                           | 15 (1.1)           |
| Peripheral vascular catheter             | 649 (73.0)                        | 398 (75.8)                        | 1047 (73.9)        |
| Urinary catheter                         | 103 (11.6)                        | 27 (5.1)                          | 130 (9.2)          |
| Intubation tube                          | 4 (0.5)                           | 1 (0.2)                           | 5 (0.4)            |
| Had surgery after admission              | 165 (18.5)                        | 57 (10.9)                         | 222 (15.7)         |
| Patients on antimicrobials               | 716 (80.3)                        | 441 (84.0)                        | 1157 (81.7)        |
| Patients on antibiotics                  | 669 (75.0)                        | 430 (81.9)                        | 1099 (77.6)        |
Table 1. Cont.

| Characteristics                                                                 | Tertiary Level Hospitals (N = 892) | Secondary Level Hospitals (N = 525) | Overall (N = 1417) |
|---------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|-------------------|
|                                                                                  | n (%)                             | n (%)                             | n (%)             |
| Average number of antimicrobials used among patients since admission             | 1.9 (±1.06)                       | 1.6 (±0.80)                       | 1.8 (±0.98)       |
| Mean (±SD)                                                                      |                                    |                                   |                   |
| Average number of antibiotics used among patients since admission                | 1.3 (±1.56)                       | 1.2 (±0.46)                       | 1.2 (±0.53)       |
| Indications for antimicrobial used (n = 1099)                                   |                                    |                                   |                   |
| Medical prophylaxis                                                             | 317 (44.3)                        | 235 (53.3)                        | 552 (47.7)        |
| Community-acquired infection                                                    | 234 (32.7)                        | 134 (30.4)                        | 368 (31.8)        |
| Hospital-acquired infection                                                     | 5 (0.7)                           | 4 (0.9)                           | 9 (0.8)           |
| Surgical prophylaxis                                                            | 191 (26.7)                        | 73 (16.6)                         | 264 (22.8)        |
| Dose and duration of antibiotics used as surgical prophylaxis (SP)              |                                    |                                   |                   |
| One dose on 1 day/multiple days (SP1)                                            | 5 (2.6)                           | 2 (2.7)                           | 7 (2.7)           |
| Multiple doses on 1 day (SP2)                                                   | 3 (1.6)                           | 9 (12.3)                          | 12 (4.6)          |
| Multiple doses > 1 day (SP3)                                                    | 183 (95.8)                        | 62 (84.9)                         | 245 (92.8)        |

SD—Standard deviation; SP—Surgical Prophylaxis.

Nearly one-sixth of patients were transferred from other hospitals and one-seventh of patients had hospitalization history in the last three months prior to the current hospital admission (Table 1). A peripheral vascular catheter was used among 73.9% of patients and 9.2% of patients had a urinary catheter (Table 1). According to the indication of antimicrobial use, 47.7% of patients received MP; 31.8% of patients received antimicrobials for CAI. SP was found among 26.7% at tertiary and 16.6% at secondary level hospitals (Table 1). Among the patients with SP, 92.8% received multiple antimicrobials for more than one day.

3.2. Antibiotics Usage According to Demographic and Clinical Characteristics

Among the surveyed patients, 74.3% and 82.3% of female patients at tertiary and secondary level hospitals received at least one antibiotic, respectively (Table 2); and 90% of patients from the 0–14 years age group, 73.8% of the 15–64 years age group, and 64.9% of the over 64 years age group received at least one antibiotic. Proportioning for different departments, 91.2% of pediatric patients, 81.4% of gynaec and obstetric patients, 78.0% of surgery patients, and 66.2% of medicine patients received at least one antibiotic. According to our findings, 98.2% of patients who had surgery after admission received antibiotics. For devices used, 86.9% of patients with urinary catheter, 84.5% of patients with peripheral vascular catheter, 80% of patients with intubation device, and 73.3% of patients with central vascular catheter received antibiotics (Table 2). Moreover, 83.7% of patients who were referred from other hospitals and 71.6% of patients with previous hospitalization in the last three months had at least one antibiotic. Overall, 81.7% of patients received at least one antimicrobial and 77.6% of patients received at least one antibiotic. On average, every patient received 1.2 (SD: ±0.53) antibiotics during the survey period.
Table 2. Use of antibiotics according to demographic and clinical characteristics of enrolled patients at tertiary and secondary level hospitals in Bangladesh from February to April 2021.

| Characteristics                        | Antibiotic Use in Tertiary Level Hospitals (N = 892) n (%) | Antibiotic Use in Secondary Level Hospitals (N = 525) n (%) | p-Value | Overall Antibiotic Use (N = 1417) n (%) |
|----------------------------------------|----------------------------------------------------------|-----------------------------------------------------------|---------|----------------------------------------|
| **Sex of patients**                    |                                                          |                                                           |         |                                        |
| Female                                 | 338 (74.3)                                               | 227 (82.3)                                               | 0.013   | 565 (77.3)                             |
| Male                                   | 331 (75.7)                                               | 203 (81.5)                                               | 0.080   | 534 (77.8)                             |
| **Age group**                          |                                                          |                                                           |         |                                        |
| 0–14 years                             | 214 (85.3)                                               | 145 (98.0)                                               | 0.000   | 359 (90.0)                             |
| 15–64 years                            | 407 (72.6)                                               | 248 (76.1)                                               | 0.249   | 655 (73.8)                             |
| 65 years and above                     | 48 (60.0)                                                | 37 (72.6)                                                | 0.142   | 85 (64.9)                              |
| **Departments**                        |                                                          |                                                           |         |                                        |
| Medicine                               | 168 (62.5)                                               | 145 (71.1)                                               | 0.050   | 313 (66.2)                             |
| Surgery                                | 189 (75.0)                                               | 123 (83.1)                                               | 0.059   | 312 (78.0)                             |
| Gynae and Obstetrics                   | 118 (78.7)                                               | 66 (86.8)                                                | 0.136   | 184 (81.4)                             |
| Pediatrics                             | 194 (87.8)                                               | 96 (99.0)                                                | 0.001   | 290 (91.2)                             |
| **Had surgery after admission** *      | 161 (97.6)                                               | 57 (100.0)                                               | 0.236   | 218 (98.2)                             |
| **Use of Devices**                     |                                                          |                                                           |         |                                        |
| Peripheral vascular catheter           | 545 (84.0)                                               | 340 (85.4)                                               | 0.528   | 885 (84.5)                             |
| Urinary catheter                       | 90 (87.4)                                                | 23 (85.2)                                                | 0.763   | 113 (86.9)                             |
| Central vascular catheter              | 7 (63.6)                                                 | 4 (100.0)                                                | 0.159   | 11 (73.3)                              |
| Intubation device                      | 4 (100.0)                                                | 0 (0.0)                                                  | 0.025   | 4 (80.0)                               |
| **History of transfer or hospitalization** |                                                      |                                                           |         |                                        |
| Patients transferred from another hospital |                                                      | 180 (82.6)                                              | 0.264   | 215 (83.7)                             |
| Hospitalization within the last 90 days | 97 (70.3)                                               | 47 (74.6)                                                | 0.529   | 144 (71.6)                             |
| **Indication for antimicrobial use**   |                                                          |                                                           |         |                                        |
| Medical Prophylaxis                    | 293 (92.4)                                               | 223 (94.9)                                               | 0.246   | 516 (93.5)                             |
| Community-Acquired Infections          | 213 (91.0)                                               | 130 (97.0)                                               | 0.028   | 343 (93.2)                             |
| Surgical Prophylaxis                   | 189 (99.0)                                               | 73 (100.0)                                               | 0.380   | 262 (99.2)                             |
| Hospital-Acquired Infections           | 5 (100.0)                                                | 4 (100.0)                                                |         | 9 (100.0)                              |

* Denominators are taken from Table 1.

3.3. Antimicrobials Used

According to the PPS, 98.8% of antimicrobials were antibiotics used during survey period and rest were antivirals (0.9%), antiparasitics (0.2%), and antifungals (0.1%). A total of 2138 encounters of antimicrobials were recorded among 1157 patients through the survey both in tertiary and secondary level hospitals (Table 3).
Table 3. Distribution of antimicrobial use according to different departments and types of hospitals in Bangladesh from February to April 2021.

| Antimicrobials Used | WHO AWaRe Classification | Medicine (N = 463) | Surgery (N = 611) | Gynae and Obstetrics (N = 479) | Pediatrics (N = 585) | Tertiary Level Hospitals (N = 1416) | Secondary Level Hospitals (N = 722) | Overall Antimicrobial Agents Used (N = 2138) |
|---------------------|--------------------------|-------------------|------------------|-----------------|-------------------|-------------------------------|---------------------------------|---------------------------------|
|                     |                          | n (%)             | n (%)            | n (%)           | n (%)             | n (%)                        | n (%)                           | n (%)                           |
| Antibiotics (In total) |                          | 455 (98.3)        | 607 (99.3)       | 478 (99.8)      | 572 (97.8)        | 1397 (98.7)                  | 715 (99.0)                      | 2112 (98.8)                     |
| Cephalosporins Group (In total) |                          | 241 (52.1)        | 347 (56.8)       | 213 (44.5)      | 285 (48.7)        | 693 (48.9)                   | 393 (54.4)                      | 1086 (51.4)                     |
| 1st-generation cephalosporins | Access                   | 0 (0.0)           | 0 (0.0)          | 23 (4.8)        | 0 (0.0)           | 23 (1.6)                     | 0 (0.0)                         | 23 (1.1)                        |
| 2nd-generation cephalosporins | Watch                   | 22 (4.8)          | 37 (6.1)         | 31 (6.5)        | 3 (0.5)           | 45 (3.2)                     | 48 (6.6)                        | 93 (4.3)                        |
| 3rd-generation cephalosporins | Watch                   | 217 (46.9)        | 304 (49.8)       | 158 (33.0)      | 275 (47.0)        | 622 (43.9)                   | 332 (46.0)                      | 954 (44.6)                      |
| 4th-generation cephalosporins | Watch                   | 2 (0.4)           | 4 (0.7)          | 1 (0.2)         | 7 (1.2)           | 2 (0.1)                      | 12 (1.7)                       | 14 (0.7)                        |
| 2nd-generation cephalosporins + beta lactamase inhibitors | Not recommended | 0 (0.0)           | 2 (0.3)          | 0 (0.0)         | 0 (0.0)           | 1 (0.1)                      | 1 (0.1)                         | 2 (0.1)                         |
| Imidazoles             | Access                   | 34 (7.3)          | 86 (14.1)        | 121 (25.3)      | 12 (2.1)          | 172 (12.1)                   | 81 (11.2)                       | 253 (11.8)                      |
| Penicillins            | Access                   | 11 (2.4)          | 116 (19.0)       | 56 (11.7)       | 80 (13.7)         | 167 (11.8)                   | 96 (13.3)                       | 263 (12.3)                      |
| Aminoglycosides        | Access                   | 2 (0.4)           | 13 (2.1)         | 7 (1.5)         | 132 (22.6)        | 137 (9.7)                    | 17 (2.4)                        | 154 (7.2)                       |
| Macrolides             | Watch                    | 82 (17.7)         | 3 (0.5)          | 31 (6.5)        | 8 (1.4)           | 60 (4.2)                     | 64 (8.9)                        | 124 (5.8)                       |
| Fluoroquinolones       | Watch                    | 25 (5.4)          | 23 (3.8)         | 40 (8.4)        | 8 (1.4)           | 53 (3.7)                     | 43 (6.0)                        | 96 (4.5)                        |
| Carbapenems            | Watch                    | 9 (1.9)           | 10 (1.6)         | 4 (0.8)         | 41 (7.0)          | 52 (3.7)                     | 12 (1.7)                        | 64 (3.0)                        |
| Beta lactam-beta lactamase inhibitors | Access                   | 41 (8.9)          | 2 (0.3)          | 1 (0.2)         | 1 (0.2)           | 42 (3.0)                     | 3 (0.4)                         | 45 (2.1)                        |
| Glycopeptides          | Watch                    | 0 (0.0)           | 0 (0.0)          | 0 (0.0)         | 5 (0.9)           | 5 (0.4)                      | 0 (0.0)                         | 5 (0.2)                         |
| Lincomamide           | Access                   | 2 (0.4)           | 3 (0.5)          | 4 (0.8)         | 0 (0.0)           | 5 (0.4)                      | 4 (0.6)                         | 9 (0.4)                         |
| Paradandin            | Access                   | 3 (0.6)           | 1 (0.2)          | 0 (0.0)         | 0 (0.0)           | 3 (0.2)                      | 1 (0.1)                         | 4 (0.2)                         |
| Anti-tubercular agents | Not-classified            | 3 (0.6)           | 1 (0.2)          | 0 (0.0)         | 0 (0.0)           | 4 (0.3)                      | 0 (0.0)                         | 4 (0.2)                         |
| Rifamycins             | Watch                    | 1 (0.2)           | 1 (0.2)          | 0 (0.0)         | 0 (0.0)           | 2 (0.1)                      | 0 (0.0)                         | 2 (0.1)                         |
| Oxazolidinones         | Reserve                  | 0 (0.0)           | 1 (0.2)          | 1 (0.2)         | 0 (0.0)           | 1 (0.1)                      | 1 (0.1)                         | 2 (0.1)                         |
| Trimethoprim-sulfonamide combinations | Access                   | 1 (0.2)           | 0 (0.0)          | 0 (0.0)         | 0 (0.0)           | 1 (0.1)                      | 0 (0.0)                         | 1 (0.0)                         |
| Antivirals             | Non-Antibiotics          | 6 (1.3)           | 2 (0.3)          | 1 (0.2)         | 10 (1.7)          | 15 (1.1)                     | 4 (0.6)                         | 19 (0.9)                        |
| Antifungals            | Non-Antibiotics          | 0 (0.0)           | 1 (0.2)          | 0 (0.0)         | 1 (0.2)           | 2 (0.1)                      | 0 (0.0)                         | 2 (0.1)                         |
| Antiparasitics         | Non-Antibiotics          | 2 (0.4)           | 0 (0.2)          | 0 (0.0)         | 2 (0.3)           | 1 (0.1)                      | 3 (0.4)                         | 5 (0.2)                         |
| Total                  |                          | 463 (100.0)       | 611 (100.0)      | 479 (100.0)     | 585 (100.0)       | 1416 (100.0)                 | 722 (100.0)                     | 2138 (100.0)                    |
3.4. Cephalosporin Groups

Among the antibiotics, the cephalosporin group constituted 51.4% (1086/2112) and the use of it in all departments was 48.9% (693) and 54.4% (393) in tertiary and secondary level hospitals, respectively (Table 3). The uses of third generation cephalosporins were documented as 49.8% (304), 46.9% (217), 47% (275), and 33% (158), respectively, in surgery, medicine, pediatrics, and gynae and obstetric wards. Among the cephalosporin groups, second generation cephalosporins (4.3%; 93) was the second highest used cephalosporin after the third generation. Moreover, the use of fourth generation cephalosporins was higher in pediatric wards (1.2%) compared to other wards (Table 3).

3.5. Other Groups of Antibiotics in Different Departments

Other than cephalosporins, penicillins (12.3%; 263), imidazoles (11.8%; 253), aminoglycosides (7.2%; 154), macrolides (5.8%; 124), fluoroquinolones (4.5%; 96), and carbapenems (3%; 64) were recorded as top few antibiotics used in the tertiary and secondary level hospitals. The use of macrolides was 17.7% (82) in medicine wards. In pediatric wards, use of aminoglycosides and carbapenems were documented as 22.6% (132) and 7% (41), respectively (Table 3).

3.6. Number of Antibiotics Used for Treating Patients after Admission

Among 1417 enrolled patients, 62.2% (882) of patients received one antibiotic that is one antibacterial agent, 12.7% (180) received two antibiotics, 2.2% three antibiotics (31), 0.4% (5) four antibiotics, and 0.1% (1) five antibiotics from admission to the date of survey (Figure 1). Use of two or more antibiotics was found high in gynae and obstetric (28.3%; 64), surgery (15.7%; 63), and pediatric wards (13.8%; 44).

Figure 1. Number of antibacterial agents used for treating patients during hospitalization on the day of the point prevalence survey at different departments of tertiary and secondary level hospitals in Bangladesh from February to April 2021.

3.7. Antibiotics Used According to AWaRE Category

According to the WHO AWaRe category, Watch group of antibiotics were used in 64.0% (1352) of patients followed by 35.6% (752) of Access and 0.1% (2) of Reserve group of antibiotics in the selected hospitals (Figure 2). In medicine wards, 78.7% (358) of patients were treated with Watch antibiotics and 20.7% (94) with Access antibiotics (Figure 2). About
62.9% (382), 36.4% (221), and 0.2% (1) of patients were treated with Watch, Access, and Reserve group of antibiotics, respectively, in surgery wards. Among the patients of gynaec and obstetric wards, 55.4% (265), 44.4% (212), and 0.2% (1) patients were treated with Watch, Access, and Reserve antibiotics, respectively. Moreover, among pediatric patients, 60.7% (347) and 39.3% (225) of children received Watch and Access antibiotics, respectively. Use of Watch antibiotics was found more in secondary hospitals (71.5%) compared to tertiary hospitals (60.2%) (p-value of 0.000). On the contrary, Access antibiotics were used more in tertiary hospitals (39.4%) compared to secondary hospitals (28.3%).

Figure 2. Antibiotics usage according to the WHO AWaRe classification at different departments of tertiary and secondary level hospitals in Bangladesh from February to April 2021.

3.8. Association between Antibiotics Use (According Aware Classification) and Characteristics of Patients and Hospitals

In the multivariable logistics model, we found that the Watch antibiotics were more likely to be used among children aged under 14 years (aOR = 6.96, 95% CI: 3.22, 15.04), patients having surgery since admission (aOR = 19.43, 95% CI: 6.99, 54.04), and patients used peripheral vascular catheter (aOR = 4.85, 95% CI: 3.52, 6.69), while it was less likely to be used in the medicine wards (aOR = 0.47, 95% CI: 0.29, 0.77) (Figure 3B). The Access antibiotics were more likely to be used among patients who had surgery since admission (aOR = 12.91, 95% CI: 8.07, 20.65), use of peripheral vascular catheter (aOR = 3.09, 95% CI: 2.24, 4.26), and patients transferred from another hospitals (aOR = 1.88, 95% CI: 1.36, 2.57) (Figure 3A).
Figure 3. (A,B): Multivariate logistic regression model for the association between Access and Watch-group antibiotics and baseline covariates at tertiary and secondary level hospitals in Bangladesh from February to April 2021.

4. Discussion

Our survey substantiated that the lion’s share of the antibiotics was used from the Watch group of the WHO Essential Medicine List (EML) based on empirical treatment. The use of Watch group antibiotics was observed in 64.0% among overall patients with higher use in secondary hospitals (71.5%) compared to tertiary hospitals (60.2%). Based on the target set by WHO for using Access group of antibiotics for 60% of patients, a reverse usage of Watch antibiotics was observed in the survey. Although, all the study hospitals had laboratory capacities, the test-based directed antimicrobial use was limited. Time consumption for the culture of bio-samples might hinder the directed treatment in hospitals. The high burden of antibiotic use also indicates a lack of implementation of guidelines in the study hospitals as most of the hospitals have no internal guidelines, and existing national guidelines are focused on few specific diseases. The study also observed the use of Reserve category antibiotics in surgery and gynaec and obstetric wards which was lower than India, high-income, upper-middle-income-, and lower-middle-income countries [21,22]. The lower use of Reserve group of antibiotics in Bangladesh is an opportunity to restrict the use by reducing commercial availability and prescription practices. The PPS was conducted following WHO PPS methodology and to the best of our knowledge, this was the foremost analysis of antibiotics in the inpatient departments of government health facilities in Bangladesh based on WHO ‘AWaRe’ classification. The prevalence of antibiotic use documented by this study was commensurable to the findings of Nigeria (81%) and Pakistan (77.6) which was higher than Botswana (70.6%), India (50%), and Ghana (51%) [21,23–26]. The findings of the survey were much higher than Southern Europe (39%), North America (37%), and the global prevalence (34%) reported by the study of Versporten et al. [14].

It is noteworthy to state that a remarkable proportion of patients received two or more antibiotics during their hospital stay at the time of survey which was lower than Ghana and Botswana [23,25]. Use of multiple antibiotics and use of two to five antibiotics in a single admission should be an important concern. The high burden of antibiotic use was observed in pediatric wards specifically in secondary level or district hospitals compared to tertiary level hospitals. In an infant hospital in Bangladesh, the prevalence of antibiotic use was 73% [27]. This may be hypothesized accounting the overuse of antibiotics among pediatric patients. Firstly, physicians might think that pediatric groups are more susceptible to infection and hospitals are the reservoir of medically concerned infections. Secondly, due to the lack of proper understanding about antimicrobials and antibiotics, parents might request or demand for newer or expensive antibiotics for their children [28].
In our PPS, the proportion of CAI was 31.8% which was similar to Pakistan (34.2%) but lower than the Global PPS with an overall prevalence of 46% [14,26]. This might be due to healthcare delivery for common CAIs (pneumonia and diarrhea) are carried out at primary level hospitals and by general practitioners (GP) in Bangladesh. In addition, about 71% of encounters of GPs were prescribed with antimicrobials [29]. Moreover, due to the pandemic of COVID-19, patient-flow might be reduced considerably. HAI was considered as one of the crucial factors for antimicrobial use though the study documented very limited frequency. This might happen due to the nationwide COVID-19 pandemic, as the general population and hospital environment were forced to adopt some infection prevention and control measures including prophylactic antibiotic use [30,31]. Due to ‘No Mask, No Service’ initiative of the government of Bangladesh during COVID-19 pandemic, the majority of the patients used mask and practiced hand washing utilizing hand sanitizer or soap [32]. Patients’ admission was also reduced compared to earlier years. In addition to this, due to the fear of COVID-19, there might be an increased use of antibiotics as medical prophylaxis which might reduce the HAI considerably [31]. The similar prevalence of antimicrobial use as medical prophylaxis was found in Pakistan (57.4%) [26], hence, there are research gaps regarding appropriate indications for antimicrobial use as medical prophylaxis [33]. Regarding SP, a single dose of antibiotic for 24 h is sufficient for preventing infections [34,35]. Nevertheless, multiple doses of antibiotics as SP for more than one day was found significantly high and the similar result was found in a Saudi Arabia (85%) [36]. The higher use of SP revealed the likelihood of practicing over-prescription which increased the financial burden to hospitals, out of pocket expenditure of patients, and antibiotic resistance to clinically concerned microorganisms. Proper administration of antibiotic prophylaxis in surgery is very much important in hospitals and requires constant efforts and collaboration between prescribers and antimicrobial stewardship program [37].

Among the Watch group antibiotics, third generation cephalosporins, ceftriaxone was remarkably high among the antibiotics used in surgery wards. The findings were higher compared with a recent study of India (24.5%) and reports of worldwide use (24.2%) published in 2021 [21,22]. Besides, the excessive use of third generation cephalosporins (Watch) is alarming as it is considered as one of the factors of extended spectrum beta-lactamase (ESBL) producing microorganisms [38,39].

Among the top five antibiotics found in the PPS of Bangladesh, three were from the Watch group such as third generation cephalosporins, macrolides, and fluoroquinolones. Among them, macrolides could not score the position in the top five in many countries including India [14,21,22]. Macrolides are used commonly for gastrointestinal diseases and respiratory infections in Bangladesh, though the excessive use of macrolides may lower the susceptibility of *Streptococcus pneumoniae* and typhoidal *Salmonella* strains [22,40–42].

The ‘AwaRe’ classification of WHO develops a general guideline on antibiotic prescribing pattern in the health facilities and the objective is to improve the monitoring system on antibiotic use. The tool needs to be adopted by countries and hospitals for rational use of antibiotics and to fight the Global combat against AMR as the tool identifies antibiotics for empiric treatment or reserving as the last hope [43,44]. However, Budd et al. showed that the use of ‘AwaRe’ Classification in England improved the use of Access antibiotics [45]. As a global antibiotic stewardship tool, WHO AWARe classification of EML should be adopted in all levels of health facilities. All the clinicians of tertiary level and secondary level hospitals should be informed and trained on current scenarios of ABU, irrational use of antibiotics, importance of AWARe classification to limit irrational antibiotic use in government health facilities. Directorate General of Drug Administration (DGDA) and pharmaceutical companies may have a major role in controlling irrational antibiotic use. Laboratory facilities of the hospitals should be vitalized and properly equipped to support the inpatient departments for directed evidence-based ABU.

The survey had some limitations. The findings from the two tertiary and two secondary level hospitals cannot be generalized for the country or this region. For the representativeness at the country level, the survey should be conducted systematically in a
population of representative sample all over Bangladesh and the results should be shared with special attention to hospital authorities, pharmaceutical companies, and policy makers. Due to the design of the study, the survey did not capture the seasonality of the antibiotic prescribing patterns. Finally, factors related with institution-wise antimicrobial resistance data, burden of infectious diseases, and supply of antibiotics were not considered in the PPS which might provide a different but valuable interpretation.

5. Conclusions and Recommendations

The PPS facilitated a benchmark on antibiotic usage at tertiary and district level hospitals illustrating excessive prescription of wide range of ‘Watch’ group of antibiotics among all age groups in Bangladesh indicating an irrational use which may facilitate extensive antibiotic resistance. For a better understanding of AMU, a robust PPS is highly recommended involving all administrative divisions of Bangladesh. The findings from this PPS at hospitals underscored the urgent need of a national antimicrobial stewardship program for promoting rational and directed antibiotic practice along with the development of local guidelines based on resistance patterns with a special emphasis on WHO AWaRe Classification, awareness building, frequent in-service training on AMR, and proper law enforcement. Moreover, the Point prevalence survey should be repeated yearly to understand the progress and monitor AMU in Bangladesh considering this study as a baseline.

Author Contributions: Conceptualization, M.R., F.C. and M.M.R.; methodology, F.C. and M.M.R.; software, M.M.R. and F.C.; validation, M.M.R. and Z.A.; formal analysis, M.M.R., P.K.G., Z.A. and F.C.; data curation, M.M.R. and P.K.G.; writing—original draft preparation, M.M.R., Z.A. and F.C.; writing—review and editing, M.M.R., Z.A., S.C., M.A.I., S.P., P.K.G., A.R., Z.H.K., K.I., N.D., M.R. and F.C.; visualization, P.K.G., F.C. and M.M.R.; supervision, F.C.; project administration—M.M.R. and F.C.; funding acquisition, F.C. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the Fleming Fund Country Grant to Bangladesh (FF48-416 FFCGB 1). icddr,b is grateful to the governments of Bangladesh, Canada, Sweden, and the UK for providing core/unrestricted support.

Institutional Review Board Statement: The survey was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board consisting of the Research Review Committee and Ethical Review Committee of icddr,b (protocol code PR-20116).

Informed Consent Statement: All study participants have provided written informed consent prior to data collection.

Data Availability Statement: The data presented in this survey are available on reasonable request from icddr,b’s research administration through the corresponding author. The data are not publicly available due to privacy restrictions and icddr,b policy.

Acknowledgments: We are grateful to our survey participants and hospital authorities for providing their support, valuable time and information. We also thank Md. Habibur Rahman and study staffs for their contribution to this project.

Conflicts of Interest: The authors declare no conflict of interest to declare. The funders had no conflict of interest with the study and contents of the manuscript.

References
1. Cassini, A.; Höögberg, L.D.; Plachouras, D.; Quattrrochi, A.; Hoxha, A.; Simonsen, G.S.; Colomb-Cotinat, M.; Kretzschmar, M.E.; Develoesschauwer, B.; Cecchini, M.; et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect. Dis. 2019, 19, 56–66. [CrossRef]
2. Jansen, W.T.M.; Van der Bruggen, J.T.; Verhoeof, J.; Fluit, A.C. Bacterial resistance: A sensitive issue Complexity of the challenge and containment strategy in Europe. Drug Resist. Updates 2006, 9, 123–133. [CrossRef] [PubMed]
3. Mark, S.; Smolinski, M.A.H.; Lederberg, J. (Eds.) Microbial Threats to Health: Emergence, Detection, and Response; National Academies Press: Washington, DC, USA, 2003.
4. Collaborators, A.R. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *Lancet* 2022, 399, 629–655. [CrossRef]

5. Singh, S.K.; Sengupta, S.; Antony, R.; Bhattacharya, S.; Mukhopadhyay, C.; Ramasubramanian, V.; Sharma, A.; Sahu, S.; Nirkhiwale, S.; Gupta, S.; et al. Variations in antibiotic use across India: Multi-centre study through Global Point Prevalence survey. *J. Hosp. Infect.* 2019, 103, 280–283. [CrossRef] [PubMed]

6. Hoque, R.; Ahmed, S.M.; Naher, N.; Islam, M.A.; Rousham, E.K.; Islam, B.Z.; Hassan, S. Tackling antimicrobial resistance in Bangladesh: A scoping review of policy and practice in human, animal and environment sectors. *PLoS ONE* 2020, 15, e0227947. [CrossRef]

7. Ahmed, S.; Korpe, P.; Ahmed, T.; Chisti, M.J.; Faruque, A.S.G. Burden and Risk Factors of Antimicrobial Use in Children Less Than 5 Years of Age with Diarrheal Illness in Rural Bangladesh. *Am. J. Trop. Med. Hyg.* 2018, 98, 1571–1576. [CrossRef]

8. Biswas, M.; Roy, M.N.; Manik, M.I.N.; Hossain, M.S.; Tapu, S.T.A.; Moniruzzaman, M.; Sultana, S. Self medicated antibiotics in Bangladesh: A cross-sectional health survey conducted in the Rajshahi City. *BMC Public Health* 2014, 14, 1–7. [CrossRef]

9. McGowan, J.E., Jr. Antimicrobial Resistance in Hospital Organisms and Its Relation to Antibiotic Use. *Rev. Infect. Dis.* 1983, 5, 1033–1048. [CrossRef]

10. WHO. The Global Action Plan on Antimicrobial Resistance. 2015. Available online: https://apps.who.int/iris/bitstream/handle/10665/254322/sea-cd-308.pdf?sequence=1&isAllowed=y (accessed on 22 May 2022).

11. WHO. WHO Access, Watch, Reserve (AWaRe) Classification for Antibiotics for Evaluation and Monitoring of Use. 2021. Available online: https://apps.who.int/iris/rest/bitstreams/1374989/retrieve (accessed on 22 May 2022).

12. Hillock, N.T.; Connor, E.; Wilson, C.; Kennedy, B. Comparative analysis of Australian hospital antimicrobial utilization, using the WHO AWaRe classification system and the adapted Australian Priority Antimicrobial List (PAL). *JAC Antimicrob. Resist.* 2021, 3, e10807. [CrossRef]

13. Mugada, V.; Mahato, V.; Andhavaram, D.; Vajhala, S.M. Evaluation of Prescribing Patterns of Antibiotics Using Selected Indicators for Antimicrobial Use in Hospitals and the Access, Watch, Reserve (AWaRe) Classification by the World Health Organization. *Turf. J. Pharm. Sci.* 2021, 18, 282–288. [CrossRef]

14. Versporten, A.; Zarb, P.; Caniaux, I.; Gros, M.-F.; Drapier, N.; Miller, M.; Jarlier, V.; Nathwani, D.; Goossens, H.; Koraqi, A.; et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: Results of an internet-based global point prevalence survey. *Lancet Glob. Health* 2018, 6, e619–e629. [CrossRef]

15. International Experts Join Forces against Superbugs at the 4th World Forum on Healthcare-Associated Infections and Antimicrobial Resistance. 2013. Available online: https://www.biomerieux.com/content/dam/biomerieux-com/investor/regulated-informations/2013/releases/pr_biomerieux_world_hai_forum_20130627_en.pdf.coredownload.pdf (accessed on 22 May 2022).

16. Goossens, H.; Nathwani, D. Global Point Prevalence Survey of Antimicrobial Consumption and Resistance. 2019. Available online: https://www.global-pps.com/wp-content/uploads/2019/02//Global-PPS-2019-protocol.pdf (accessed on 22 May 2022).

17. WHO. WHO Methodology for Point Prevalence Survey on Antibiotic Use in Hospitals, Version 1.1. 2018. Available online: https://apps.who.int/iris/bitstream/handle/10665/254322/sea-cd-308.pdf?sequence=1&isAllowed=y (accessed on 22 May 2022).

18. Le, N.K.; Hf, W.; Vu, P.D.; Khu, D.T.K.; Le, H.T.; Hoang, B.T.N.; Vo, V.T.; Lam, Y.M.; Vu, D.T.V.; Nguyen, T.H.; et al. High prevalence of hospital-acquired infections caused by gram-negative carbapenem resistant strains in Vietnamese pediatric ICUs: A multi-centre point prevalence survey. *Medicine* 2016, 95, e4099. [CrossRef] [PubMed]

19. Munchkof, W. Antibiotics for surgical prophylaxis. *Aust. Prescr.* 2005, 28, 38–40. [CrossRef]

20. Management Information System. HEALTH BULLETIN 2019. 2020. Available online: https://old.dghs.gov.bd/images/docs/Publications/Health%20Bulletin%202019%20Print%20Version%20(2)-Final.pdf (accessed on 22 May 2022).

21. Panditrao, A.M.; Shafiq, N.; Chatterjee, S.; Pathak, A.; Trivedi, N.; Sadasivam, B.; Kshirsagar, N.; Kaul, R.; Biswal, M.; Kakkar, A.; et al. A multicentre point prevalence survey (PPS) of antimicrobial use amongst admitted patients in tertiary care centres in India. *J. Antimicrob. Chemother.* 2021, 76, 1094–1101. [CrossRef]

22. Pauwels, I.; Versporten, A.; Drapier, N.; Vlieghe, E.; Goossens, H.; Global. PPS.n. Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): Results from a worldwide point prevalence survey in 69 countries. *J. Antimicrob. Chemother.* 2021, 76, 1614–1624. [CrossRef]

23. Labi, A.K.; Obeng-Nkruhah, N.; Naray, E.T.; Bjerrum, S.; Ado-Aryee, N.A.; Ofori-Adjei, Y.A.; Yawson, A.E.; Newman, M.J. Antibiotic use in a tertiary healthcare facility in Ghana: A point prevalence survey. *Antimicrob. Resist. Infect. Control* 2018, 7, 15. [CrossRef]

24. Ogunleye, O.O.; Oyawo, M.R.; Odunuga, P.T.; Kalejaye, F.; Yinka-Ogunleye, A.F.; Olalekan, A.; Ogundele, S.O.; Ebruke, B.E.; Kalada Richard, A.; Anand Paramadhas, B.D.; et al. A multicentre point prevalence study of antibiotics utilization in hospitalized patients in an urban secondary and a tertiary healthcare facilities in Nigeria: Findings and implications. *Expert Rev. Anti-Infect. Ther.* 2022, 20, 297–306. [CrossRef]

25. Anand Paramadhas, B.D.; Tiroyakgosi, C.; Mpinda-Joseph, P.; Morokotso, M.; Matome, M.; Sinkala, F.; Gaolebe, M.; Malone, B.; Molosiwa, E.; Shannmugam, M.G.; et al. Point prevalence study of antimicrobial use among hospitals across Botswana; findings and implications. *Expert Rev. Anti-Infect. Ther.* 2019, 17, 535–546. [CrossRef]

26. Saleem, Z.; Hassali, M.A.; Versporten, A.; Godman, B.; Hashmi, F.K.; Goossens, H.; Saleem, F. A multicenter point prevalence survey of antibiotic use in Punjab, Pakistan: Findings and implications. *Expert Rev. Anti-Infect. Ther.* 2019, 17, 285–293. [CrossRef]
Antibiotics 2022, 11, 810

27. Boone, K.; Morris, S.K.; Doshi, S.; Black, J.; Mohsin, M.; Ahmed, T.; Al Mahmud, A.; Roth, D.E. Antimicrobial Prescribing during Infant Hospital Admissions in a Birth Cohort in Dhaka, Bangladesh. *J. Trop. Pediatr.* 2021, 67, fmaa093. [CrossRef]

28. Nguyen, N.V.; Do, N.T.T.; Nguyen, C.T.K.; Tran, T.K.; Ho, P.D.; Nguyen, H.H.; Vu, H.T.L.; Wertheim, H.E.L.; van Doorn, H.R.; Lewycka, S. Community-level consumption of antibiotics according to the AWARe (Access, Watch, Reserve) classification in rural Vietnam. *JAC Antimicrob. Resist.* 2020, 2, dlaa048. [CrossRef] [PubMed]

29. UK Health Security Agency. English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR): Report 2019 to 2020. 2020. Available online: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1069632/espaur-report-2020-to-2021-16-Nov-FINAL-v2.pdf (accessed on 22 May 2022).

30. Akhtar, Z.; Mah-E-Muneer, S.; Islam, M.A.; Chowdhury, S.; Rashid, M.M.; Ahmed, M.S.; Khan, Z.; Hassan, M.Z.; Parveen, S.; Rahman, N.D.M.; et al. Antibiotics Use and Its Knowledge in the Community: A Mobile Phone Survey during the COVID-19 Pandemic in Bangladesh. *Antibiotics* 2021, 10, 1052. [CrossRef] [PubMed]

31. Mah-E-Muneer, S.; Hassan, M.Z.; Biswas, M.A.A.J.; Rahman, F.; Akhtar, Z.; Das, P.; Islam, M.A.; Chowdhury, F. Use of Antimicrobials among Suspected COVID-19 Patients at Selected Hospitals, Bangladesh: Findings from the First Wave of COVID-19 Pandemic. *Antibiotics* 2021, 10, 738. [CrossRef] [PubMed]

32. Desk, Tribune. ‘No Mask, No Service’. Dhaka Tribune. 2020. Available online: https://archive.dhakatribune.com/bangladesh/government-affairs/2020/10/31/no-mask-no-entry (accessed on 22 May 2022).

33. Ioannou, P.; Karakonstantis, S.; Schouten, J.; Kostyanev, T.; Charani, E.; Vlahovic-Palcevski, V.; Kofteridis, D.P. Indications for medical antibiotic prophylaxis and potential targets for antimicrobial stewardship intervention: A narrative review. *Clin. Microbiol. Infect.* 2022, 28, 362–370. [CrossRef] [PubMed]

34. Desk, Tribune. ‘No Mask, No Service’. Dhaka Tribune. 2020. Available online: https://archive.dhakatribune.com/bangladesh/government-affairs/2020/10/31/no-mask-no-entry (accessed on 22 May 2022).

35. Ioannou, P.; Karakonstantis, S.; Schouten, J.; Kostyanev, T.; Charani, E.; Vlahovic-Palcevski, V.; Kofteridis, D.P. Indications for medical antibiotic prophylaxis and potential targets for antimicrobial stewardship intervention: A narrative review. *Clin. Microbiol. Infect.* 2022, 28, 362–370. [CrossRef] [PubMed]

36. Yaser, M.; Aljabri, A.K.; Alsaaed, F.N.; Rizk, L.M.; Alahmadi, R.Y.; Aljuhani, S.R.; Aljohani, S.H.; Al Thagfan, S.S.; Alamuddin, W.A.; Alonazie, W.S.; et al. A prospective antibiotic point prevalence survey in two primary referral hospitals during and after pilgrims stay in Madinah, Saudi Arabia. *Trop. J. Pharm. Res.* 2020, 19, 391–399. [CrossRef]

37. Segala, F.V.; Murri, R.; Taddei, E.; Giovannenze, F.; Del Vecchio, P.; Birocchi, E.; Taccari, F.; Cauda, R.; Fantoni, M. Antibiotic appropriateness and adherence to local guidelines in perioperative prophylaxis: Results from an antimicrobial stewardship intervention. *Antimicrob. Resist. Infect. Control* 2020, 9, 1–6. [CrossRef]

38. Larramendy, S.; Gaultier, A.; Fournier, J.P.; Caillon, J.; Moret, L.; Beaudeau, F. Local characteristics associated with higher prevalence of ESBL-producing Escherichia coli in community-acquired urinary tract infections: An observational, cross-sectional study. *J. Antimicrob. Chemother.* 2021, 76, 789–795. [CrossRef]

39. Paterson, D.L.; Bonomo, R.A. Extended-spectrum beta-lactamases: A clinical update. *Clin. Microbiol. Rev.* 2005, 18, 657–686. [CrossRef] [PubMed]

40. Crump, J.A.; Sjolund-Karlsson, M.; Gordon, M.A.; Parry, C.M. Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections. *Clin. Microbiol. Rev.* 2015, 28, 901–937. [CrossRef]

41. Robert, W.; Frenck, J.A.M.; Nakhla, I.; Sultan, Y.; Putnam, S.; Wierzba, T.; Knirsch, M.M.C. Short-Course Azithromycin for the Treatment of Uncomplicated Typhoid Fever in Children and Adolescents. *Clin. Infect. Dis.* 2004, 38, 951–957. [CrossRef] [PubMed]

42. Lubell, Y.; Turner, P.; Ashley, E.A.; White, N.J. Susceptibility of bacterial isolates from community-acquired infections in sub-Saharan Africa and Asia to macrolide antibiotics. *Trop. Med. Int. Health* 2011, 16, 1192–1205. [CrossRef] [PubMed]

43. WHO. In the Face of Slow Progress, WHO Offers a New Tool and Sets a Target to Accelerate Action against Antimicrobial Resistance. 2019. Available online: https://www.who.int/news/item/18-06-2019-in-the-face-of-slow-progress-who-offers-a-new-tool-and-sets-a-target-to-accelerate-action-against-antimicrobial-resistance (accessed on 22 May 2022).

44. WHO. The Selection and Use of Essential Medicines. 2017. Available online: https://www.who.int/publications/i/item/9789241210157 (accessed on 22 May 2022).

45. Budd, E.; Cramp, E.; Sharland, M.; Hand, K.; Howard, P.; Wilson, P.; Wilcox, M.; Muller-Pebody, B.; Hopkins, S. Adaptation of the WHO Essential Medicines List for national antibiotic stewardship policy in England: Being AWARe. *J. Antimicrob. Chemother.* 2019, 74, 3384–3389. [CrossRef] [PubMed]